Wayne, PA — May 13, 2026 — To support continued growth, Facet Life Sciences, a product pathmaker for emerging biotechnology, pharmaceutical, and device developers, today announced executive team changes. Facet helps lean science teams navigate FDA approval and commercialization in complex, high-risk markets. This growth reflects a strengthened commitment to providing clarity, direction, and stability to accelerate our clients’ programs with confidence. Transitions will take effect between Q2 and Q3 2026.
- Tom Hallam, Ph.D., MBA, will serve as Facet’s President and Chief Operating Officer, while Lane Jaeckle Santos, Ph.D., RAC, assumes the role of Strategic Program Champion and Regulatory Services Team Manager.
- Lisa Jenkins VanLuvanee, Ph.D., steps up as Facet’s first Chief Values Officer.
- Ken VanLuvanee will maintain his roles as Facet’s CEO & Board Chairman to maximize the company’s position as a trusted advisor to developers seeking a feasible path to and through the FDA.
“This is an exciting time for Facet,” says Ken VanLuvanee, CEO. “Our clear-eyed focus has always been on creating and executing development strategies for emerging life sciences companies. By expanding and empowering our executive team, we position Facet exactly where our customers need us to be — a growing company with strong leadership, positioned to deliver for them now and into the future.”
“We are entering this next chapter with a clear focus on delivering meaningful impact for our clients,” says Tom Hallam, Ph.D., MBA, President & COO. “At Facet, we bring experience and judgment to complex decision-making environments, and that remains core to who we are. These leadership updates position us to deliver that impact with greater consistency and scale.”
“Becoming Facet’s first Chief Values Officer is an honor that reflects everything this team has built over the past 14 years,” says Lisa Jenkins VanLuvanee, Ph.D., CVO. “My focus is on cultivating the mindset and culture required to operate at the frontier of innovation — one defined by intellectual courage, analytical discipline, and the strategic judgment to guide clients and colleagues through uncharted territory.”
These changes represent Facet’s expanded capacity and an era of improved collaboration across our expert teams, both internally and with our dedicated scientific partners.
About Facet Life Sciences
Facet Life Sciences supports emerging life sciences companies looking for feasible pathways to and through the FDA. With deep expertise across therapeutic applications, Facet provides regulatory strategy, FDA submission leadership, gap analysis, regulatory writing services, commercial strategy, and more. The multidisciplinary team of experts helps innovators navigate regulatory complexity and build cost-conscious programs designed for both FDA approval and real-world success.
Follow Facet Life Sciences on LinkedIn: linkedin.com/company/facet-life-sciences
Tom Hallam, Ph.D., MBA
President & COO
tom.hallam@facetls.com
gET sOCIAL